A vaccine strategy involving formulation changes, an initial escalating dose, and a longer wait for booster immunization results in more-effective antibody production against HIV in rhesus monkeys, a study finds.
Engineered viruses that don’t replicate provide a tractable model for scientists to safely study SARS-CoV-2, including research into vaccine efficacy and emerging variants.